NCT03671135 is a NA clinical trial of TCA Intrastromal Inlay in Presbyopia, sponsored by Allotex, Inc..

Who is sponsoring NCT03671135?

NCT03671135 is sponsored by Allotex, Inc..

What drugs are being tested in NCT03671135?

Interventions in NCT03671135: TCA Intrastromal Inlay.

What condition does NCT03671135 study?

NCT03671135 studies Presbyopia.

Is NCT03671135 still recruiting?

NCT03671135 is currently terminated. Last updated 23 February 2024.

Last reviewed 2024-02-23 · How we verify

NCT03671135

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of an Intrastromal Transform™ Corneal Allograft (TCA) for Presbyopia Correction

Terminated NA Last updated 23 February 2024

What this trial tests

NA trial testing TCA Intrastromal Inlay in Presbyopia in 121 participants. Terminated before completion.

Timeline

9 August 2018

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Allotex, Inc.
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	121
Start date	9 August 2018
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	4 locations across Belgium, United Kingdom, Ireland

Drugs / interventions tested

TCA Intrastromal Inlay

Conditions studied

Presbyopia — all drugs for Presbyopia →

Sponsor

Allotex, Inc.

Who can join

Eligibility, any sex, with Presbyopia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this clinical study is to evaluate the safety and effectiveness of intrastromal implantation of the Allotex TransForm corneal allograft (TCA) for improving near vision in presbyopic subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Presbyopia

Currently open trials in the same condition.

NCT07444658 — Performance of Two Daily Disposable Multifocal Contact Lenses · NA · recruiting
NCT07284966 — Comfort and Vision With TOTAL30 Multifocal Lenses · recruiting
NCT07077967 — Luminous Efficiency Function V(λ)' of Patients That Underwent Pseudophakic Presbyopic Corrections With EDOF IOLs · recruiting
NCT07113210 — Quality of Life in Presbyopic Patients Who Are Treated With Qlosi · Phase 4 · recruiting
NCT06948357 — Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia Patients · Phase 2 · recruiting

Other Allotex, Inc. trials

Trials by the same sponsor.

NCT06310252 — Safety and Efficacy of an Intrastromal Transform Corneal Allograft (TCA) for Presbyopia Correction - Long Term Follow-up · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03671135 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Allotex, Inc.
Last refreshed: 23 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03671135.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing